Structural formula
Ball-and-stick model
Clinical data
Trade namesLevo-Dromoran
Other namesRo 1-5431[1]
Routes of
Oral, intravenous, subcutaneous, intramuscular
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Bioavailability70% (oral); 100% (IV)
Protein binding40%
Elimination half-life11–16 hours
  • (1R,9R,10R)-17-Methyl-17-azatetracyclo[,10.02,7]heptadeca-2(7),3,5-trien-4-ol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.000.912 Edit this at Wikidata
Chemical and physical data
Molar mass257.377 g·mol−1
3D model (JSmol)
  • CN1CC[C@]23CCCC[C@H]2[C@H]1Cc4c3cc(O)cc4
  • InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1 checkY
 ☒NcheckY (what is this?)  (verify)

Levorphanol (brand name Levo-Dromoran) is an opioid medication used to treat moderate to severe pain.[1][2][3] It is one of two enantiomers of the compound racemorphan.

It was first described in Germany in 1946.[4] The drug has been in medical use in the United States since 1953.[5]


Levorphanol acts predominantly as an agonist of the μ-opioid receptor (MOR), but is also an agonist of the δ-opioid receptor (DOR), κ-opioid receptor (KOR), and the nociceptin receptor (NOP), as well as an NMDA receptor antagonist and a serotonin-norepinephrine reuptake inhibitor (SNRI).[5] Levorphanol, similarly to certain other opioids, also acts as a glycine receptor antagonist and GABA receptor antagonist at very high concentrations.[6] Levorphanol is 6 to 8 times as potent as morphine at the MOR.[citation needed]

Relative to morphine, levorphanol lacks complete cross-tolerance[7] and possesses greater intrinsic activity at the MOR.[7] The duration of action is generally long compared to other comparable analgesics and varies from 4 hours to as much as 15 hours. For this reason levorphanol is useful in palliation of chronic pain and similar conditions. Levorphanol has an oral to parenteral effectiveness ratio of 2:1, one of the most favorable of the strong narcotics. Its antagonism of the NMDA receptor, similar to those of the phenylheptylamine open-chain opioids such as methadone or the phenylpiperidine ketobemidone, make levorphanol useful for types of pain that other analgesics may not be as effective against, such as neuropathic pain.[8] Levorphanol's exceptionally high analgesic efficacy in the treatment of neuropathic pain is also conferred by its action on serotonin and norepinephrine transporters, similar to the opioids tramadol and tapentadol, and mutually complements the analgesic effect of its NMDA receptor antagonism.[9]

Levorphanol shows a high rate of psychotomimetic side effects such as hallucinations and delirium, which have been attributed to its binding to and activation of the KOR.[10] At the same time however, activation of this receptor as well as of the DOR have been determined to contribute to its analgesic effects.[10]


Levorphanol and its stereoisomer dextrorphan, the enantiomers of the racemic mixture racemorphan.
Levorphanol and its stereoisomer dextrorphan, the enantiomers of the racemic mixture racemorphan.

Chemically, levorphanol belongs to the morphinan class and is (−)-3-hydroxy-N-methyl-morphinan.[7] It is the "left-handed" (levorotatory) stereoisomer of racemorphan, the racemic mixture of the two stereoisomers with differing pharmacology. The "right-handed" (dextrorotatory) enantiomer of racemorphan is dextrorphan (DXO), an antitussive, potent dissociative hallucinogen (NMDA receptor antagonist), and weakly active opioid. DXO is an active metabolite of the pharmaceutical drug dextromethorphan (DXM), which, analogously to DXO, is an enantiomer of the racemic mixture racemethorphan along with levomethorphan, the latter of which has similar properties to those of levorphanol.

Society and culture


Levorphanol is the INN, BAN, and DCF.[1][2][3] As the medically used tartrate salt, the drug is also known as levorphanol tartrate (USAN, BANM).[1][3] The former developmental code name of levorphanol at Roche was Ro 1-5431.[1][3]


As the tartrate salt, levorphanol is marketed by Sentynl Therapeutics and Virtus Pharmaceuticals in the U.S., and Canada under the brand name Levo-Dromoran.[2]


Levorphanol is listed under the Single Convention On Narcotic Drugs 1961 and is regulated like morphine in most countries. In the U.S., it is a Schedule II Narcotic controlled substance with a DEA ACSCN of 9220 and 2013 annual aggregate manufacturing quota of 4.5 kilos. The salts in use are the tartrate (free base conversion ratio 0.58) and hydrobromide (0.76).[11]

See also


  1. ^ a b c d e Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 656–. ISBN 978-1-4757-2085-3.
  2. ^ a b c Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 606–. ISBN 978-3-88763-075-1.
  3. ^ a b c d Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Medi a. pp. 165–. ISBN 978-94-011-4439-1.
  4. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 527. ISBN 9783527607495.
  5. ^ a b Gudin J, Fudin J, Nalamachu S (January 2016). "Levorphanol Use: Past, Present and Future". Postgraduate Medicine. 128 (1): 46–53. doi:10.1080/00325481.2016.1128308. PMID 26635068. S2CID 3912175.
  6. ^ Osborne NN (22 October 2013). Selected Topics from Neurochemistry. Elsevier Science. pp. 244–. ISBN 978-1-4832-8635-8.
  7. ^ a b c Davis MP, Glare PA, Hardy J (2009) [2005]. Opioids in Cancer Pain (2nd ed.). Oxford, UK: Oxford University Press. ISBN 978-0-19-157532-7.
  8. ^ Prommer E (March 2007). "Levorphanol: the forgotten opioid". Supportive Care in Cancer. 15 (3): 259–64. doi:10.1007/s00520-006-0146-2. PMID 17039381. S2CID 10916508.
  9. ^ Nalamachu, S; Gudin, J (Apr 2016). "Levorphanol, another choice in opioid rotation". J Pain. 17: S14. doi:10.1016/j.jpain.2016.01.056.
  10. ^ a b Bruera ED, Portenoy RK (12 October 2009). Cancer Pain: Assessment and Management. Cambridge University Press. pp. 215–. ISBN 978-0-521-87927-9.
  11. ^ "Conversion Factors for Controlled Substances". Diversion Control Division. U.S. Department of Justice • Drug Enforcement Administration.